HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
Molecules · 18.06.2025 · 30 (12) · 2645
DOI: 10.3390/molecules30122645 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 18.06.2025. Verfasst von Pamela Trillo Aliaga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, IEO-European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) can harbour different HER2 alterations: HER2 protein overexpression (2–35%), HER2 gene amplification (2–20%), and gene mutations (1–4%). The discovery of the HER2 gene in the 1980s raised great expectations for the treatment of several tumours. However, it was only in 2004 that HER2 mutations were identified, and they currently represent a key druggable target in NSCLC. Despite numerous strengths, there is only one FDA/EMA-approved targeted therapy, an antibody-drug conjugate (ADC) called trastuzumab deruxtecan for pretreated patients with HER2 mutant NSCLC. In the first-line treatment, the standard of care (SoC) remains chemotherapy with or without immunotherapy. In the past, pan-HER tyrosine kinase inhibitors (TKIs) were extensively studied with poor results. But, two newly developed HER2-specific TKIs with low EGFR WT inhibition (BAY2927088 and zongertinib) reported encouraging results and received the breakthrough therapy designation from the FDA. Ongoing clinical trials are investigating new agents. This review focuses on HER2 alterations. Additionally, the anti-HER2 therapies explored so far will be discussed in detail, including the following: HER2 inhibitors (pan-inhibitors and selective inhibitors), monoclonal antibodies (mAbs), and ADCs. A section of this paper is dedicated to the role of immunotherapy in HER2-altered NSCLC. The last section of this paper focuses on the drugs under development and their challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, IEO-European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
- Department of Oncology and Haematology (DIPO), University of Milan, 20122 Milan, Italy.
ORCID-Profile: Pamela Trillo Aliaga, Gianluca Spitaleri, Ilaria Attili, Ester Del Signore, Antonio Passaro
Förderung
- Italian Ministry of Health
Zitieren
APA
Trillo Aliaga, P., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Del Signore, E., Passaro, A., & de Marinis, F. (2025). HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top. Molecules, 30(12), 2645. https://doi.org/10.3390/molecules30122645
Vancouver
Trillo Aliaga P, Spitaleri G, Attili I, Corvaja C, Battaiotto E, Angelopoulos PA, et al. HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top. Molecules. 2025;30(12):2645. doi:10.3390/molecules30122645
BibTeX
@article{TrilloAliaga2025,
author = {Trillo Aliaga, Pamela and Spitaleri, Gianluca and Attili, Ilaria and Corvaja, Carla and Battaiotto, Elena and Angelopoulos, Panagiotis Agisilaos and Del Signore, Ester and Passaro, Antonio and de Marinis, Filippo},
title = {HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top},
journal = {Molecules},
year = {2025},
volume = {30},
number = {12},
pages = {2645},
doi = {10.3390/molecules30122645}
}
EUVIMED